FLT3-D835 in R/R AML: gilteritinib superior to salvage chemo (ADMIRAL, Perl 2019 — pre-sp...
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | BMA-FLT3-D835-AML-RR |
|---|---|
| Tipo | Relevancia terapéutica |
| Situación | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Enfermedades | DIS-AML |
| Fuentes | SRC-ADMIRAL-PERL-2019 SRC-CIVIC SRC-ELN-AML-2022 SRC-NCCN-AML-2025 |
Hechos relativos a la posibilidad de adoptar medidas
| Biomarcador | BIO-FLT3-D835 |
|---|---|
| Variante | Mutación del punto TKD (D835Y/V; recaída/refractaria) |
| Enfermedad | DIS-AML |
| El nivel de ESCAT | IA |
| Combinaciones recomendadas | gilteritinib monotherapy (2L bridge to allo-SCT), gilteritinib + venetoclax + azacitidine (off-label, trial) |
| Monoterapia contraindicada | quizartinib (inactive vs D835), sorafenib (poor activity vs D835 in clinical practice) |
| Resumen de las pruebas | FLT3-D835 in R/R AML: gilteritinib superior to salvage chemo (ADMIRAL, Perl 2019 — pre-specified subset analysis showed activity across both ITD and D835/TKD; D835 subset response rates similar to ITD overall). Gilteritinib is preferred type-I FLT3i for D835-mutant R/R disease. Quizartinib remains contraindicated (no D835 activity). |
Notas
ESCAT IA. OncoKB Level 1. Per task brief: D835 R/R is well- characterized for gilteritinib (type-I) advantage over type-II.
Utilizado por
Relevancia terapéutica
BMA-FLT3-ITD-AML-RR- FLT3-ITD in relapsed/refractory AML: gilteritinib monotherapy superior to salvage chemo (...